
INVESTOR CENTRE
Dear Investors,
Welcome to Myopharm, a clinical-stage company with a strong clinical pipeline in developing targeted therapies for multiple chronic diseases.
Myopharm has expert management coupled with an efficient business model and an ambitious roadmap, with R&D and manufacturing at the core of our development. Myopharm believes in long-term and sustainable partnerships.
With the Type 2 diabetes population expected to double to over 600 million worldwide by 2045, and the diabetes market expected to grow from $20.4B to over $58.7B within 2025, we believe that your health cannot afford to wait.
Share Registry
Corporate Governance
Shareholder Updates
17/03/2025
Dr George Tachas and Advait Padhye joins Myopharm’s Scientific Team
06/02/2025
Myopharm strengthens clinical development team with appointment of Tamara Miller